15 million doses of J&J coronavirus vaccine ruined in US by 'human error'

The problem at the plant has been reported to be an ingredient mix-up due to "human error"

Johnson & Johnson
Photo: Reuters
IANS New York
2 min read Last Updated : Apr 01 2021 | 3:16 PM IST

Errors at a manufacturing plant in the US has ruined 15 million potential doses of the Johnson & Johnson Covid-19 vaccine, The New York Times reported.

The quality issue was identified at a manufacturing plant in Baltimore run by Emergent Biosolutions, a site not yet authorised to manufacture drug substance for Johnson & Johnson's Covid-19 vaccine.

The error is delaying the authorisation of the plant's production lines as the US Food and Drug Administration (FDA) investigates what occurred.

Emergent Biosolutions is also a manufacturing partner for AstraZeneca, whose Covid-19 vaccine has not yet been approved in the US.

The problem at the plant has been reported to be an ingredient mix-up due to "human error".

No issues were reported for the Johnson & Johnson vaccine doses that are being delivered and used in the US currently though.

Those doses were manufactured in the Netherlands, where production lines have been fully approved by federal regulators, the Times reported on Wednesday.

Johnson & Johnson said in a statement that the "quality control process identified one batch of drug substance that did not meet quality standards at Emergent Biosolutions, a site not yet authorized to manufacture drug substance for our Covid-19 vaccine."

"This batch was never advanced to the filling and finishing stages of our manufacturing process," the company said.

According to a report in The Verge, about 30 per cent of the US population has received at least one dose of a Covid-19 vaccine so far.

--IANS

gb/in

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusJohnson & JohnsonUnited StatesVaccineCoronavirus Vaccine

First Published: Apr 01 2021 | 3:12 PM IST

Next Story